Researchers at Vaxart Inc. and the Center for Vaccine Development at the University of Maryland School of Medicine evaluated the safety and immunogenicity of an oral norovirus vaccine tablet, VXA-G1.1-NN. Results indicate that the vaccine was safe and well tolerated while eliciting robust systemic and mucosal immune responses in adults aged 55 to 80 years.
Oral norovirus vaccine passes safety testing with a strong immune response in older adults
